The Latest Breaking News from AMGN

Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that surpassed analyst expectations after markets closed on Tuesday.

Three major pharmaceutical companies — Amgen Inc. (NASDAQ:AMGN), Eli Lilly and Co (NYSE:LLY), and UCB SA (OTC:UCBJY) (OTC:UCBJF) — are suing U.S. Secretary of Health and Human Services (HHS) Robert F. Kennedy Jr. over the way his department is handling a drug discount program.

Amgen Inc‘s (NASDAQ:AMGN) second quarter results demonstrate ongoing development of its late-stage pipeline “to offset end-of-decade losses-of-exclusivity," according to Goldman Sachs.

Amgen has notably outpaced the broader market and the healthcare sector in 2025, and analysts remain cautiously optimistic about the stock’s prospects.

Amgen is set to release its second-quarter earnings next month, and analysts are projecting modest single-digit growth in profit.

Amgen Inc (NASDAQ:AMGN) shares are trading lower by 5.7% to $272.88 Monday afternoon after the company released full results from part one of its phase two study of MariTide, its investigational obesity treatment.

Amgen has underperformed the Pharmaceuticals industry over the past year, but analysts are moderately optimistic about the stock’s prospects.

Although Amgen has lagged behind the broader market over the past year, Wall Street analysts remain cautiously optimistic about the company’s long-term outlook.

June S&P 500 E-Mini futures (ESM25) are up +1.18%, and June Nasdaq 100 E-Mini futures (NQM25) are up +1.68% this morning as forecast-beating quarterly results from Microsoft and Meta boosted sentiment.

Amgen is scheduled to report its first-quarter results next month, and analysts expect a single-digit earnings growth.

As Bristol-Myers has outperformed the Dow recently, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.